Statin adjunctive therapy shortens the duration of TB treatment in mice.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Journal:The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 6
The repurposing of existing agents may accelerate TB drug development. Recently, we reported that the lipid-lowering drug simvastatin, when added to the first-line antitubercular regimen, reduces the lung bacillary burden in chronically infected mice.